Rituximab in Lymphoma and Chronic Lymphocytic Leukemia: A Clinical Practice Guideline, Version 3

This clinical practice guideline discusses the use of rituximab as a treatment option for adult patients with lymphoma or chronic lymphocytic leukemia (CLL), including combination chemotherapy, rituximab monotherapy, and rituximab maintenance therapy for patients who respond to treatment with combination chemotherapy and/or rituximab. Screening for surface antigen for hepatitis B (HBsAg) and hepatitis B core antibody (HBcAb) prior to treatment with rituximab is also discussed. Outcomes of interest are overall survival, disease control (overall, progression free, failure-free, or disease free survival; response duration), response rate, quality of life, and toxicity.